ECM
AXSM icon

Everence Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Everence Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
1,333
+68
+5% +$14.7K 0.02% 594
2026
Q1 		$214K Buy
1,265
+115
+10% +$19.9K 0.01% 723
2025
Q4 		$210K Buy
+1,150
New +$161K 0.01% 731

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Everence Capital Management's AXSM Position: Q2 2026 in Review

Everence Capital Management increased its Axsome Therapeutics (AXSM) stake by 5.4% in Q2 2026, buying an estimated $14.7K and bringing the position to 1,333 shares worth $326K. The position accounts for 0.02% of the portfolio, ranked #594.

Everence Capital Management first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Everence Capital Management held 1,333 shares of Axsome Therapeutics worth $326K as of Q2 2026.
  • Everence Capital Management bought 68 Axsome Therapeutics shares in Q2 2026, an estimated $14.7K.
  • Axsome Therapeutics made up 0.02% of Everence Capital Management's portfolio in Q2 2026, its #594 holding.
  • Everence Capital Management first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.